Journal publications

Export 80 results:
Author Title Type [ Year(Asc)]
Filters: Type is Journal Article  [Clear All Filters]
Stirrup OT, Asboe D, Pozniak A, Sabin C, Gilson R, Mackie NE, Tostevin A, Hill T, Dunn DT, UK Collaborative Group on HIV Drug Resistance and the UK Collaborative HIV Cohort Study.  2020.  Continuation of emtricitabine/lamivudine within combination antiretroviral therapy following detection of the M184V/I HIV-1 resistance mutation. HIV Med.
Stirrup OT, Sabin CA, Phillips AN, Williams I, Churchill D, Tostevin A, Hill T, Dunn DT, UK Collaborative Group on HIV Drug Resistance and the UK Collaborative HIV Cohort Study.  2019.  Associations between baseline characteristics, CD4 cell count response and virological failure on first-line efavirenz + tenofovir + emtricitabine for HIV.. J Virus Erad. 5(4):204-211.
Le Vu S, Ratmann O, Delpech V, Brown AE, O Gill N, Tostevin A, Dunn D, Fraser C, Volz E.  2019.  HIV-1 transmission patterns in men who have sex with men: insights from genetic source attribution analysis.. AIDS Res Hum Retroviruses.
Mbisa JL, Kirwan P, Tostevin A, Ledesma J, Bibby DF, Brown A, Myers R, Hassan AS, Murphy G, Asboe D et al..  2018.  Determining the origins of HIV-1 drug-resistant minority variants in people who are recently infected using phylogenetic reconstruction.. Clin Infect Dis.
Lodi S, Günthard HF, Dunn DT, Garcia F, Logan R, Jose S., Bucher HC, Scherrer AU, Schneider M-P, Egger M et al..  2018.  Effect of immediate initiation of antiretroviral treatment on the risk of acquired HIV drug resistance.. AIDS. 32(3):327-335.
Stirrup OT, Dunn DT.  2018.  Estimation of delay to diagnosis and incidence in HIV using indirect evidence of infection dates.. BMC Med Res Methodol. 18(1):65.
Volz EM, Le Vu S, Ratmann O, Tostevin A, Dunn D, Orkin C, O'Shea S, Delpech V, Brown A, Gill N et al..  2018.  Molecular Epidemiology of HIV-1 Subtype B Reveals Heterogeneous Transmission Risk: Implications for Intervention and Control.. J Infect Dis. 217(10):1522-1529.
Ragonnet-Cronin M, Hué S, Hodcroft EB, Tostevin A, Dunn D, Fawcett T, Pozniak A, Brown AE, Delpech V, Brown AJLeigh.  2018.  Non-disclosed men who have sex with men in UK HIV transmission networks: phylogenetic analysis of surveillance data.. Lancet HIV. 5(6):e309-e316.
Stirrup OT, Dunn DT, Tostevin A, Sabin CA, Pozniak A, Asboe D, Cox A, Orkin C, Martin F, Cane P.  2018.  Risk factors and outcomes for the Q151M and T69 insertion HIV-1 resistance mutations in historic UK data.. AIDS Res Ther. 15(1):11.
Geretti AM, White E, Orkin C, Tostevin A, Tilston P, Chadwick D, Leen C, Sabin C, Dunn DT.  2018.  Virological outcomes of boosted protease inhibitor-based first-line ART in subjects harbouring thymidine analogue-associated mutations as the sole form of transmitted drug resistance.. J Antimicrob Chemother.
Schultze A, Paredes R, Sabin CA, Phillips AN, Pillay D, Mackie N, Castagna A, Chadwick D, Falconer K, Geretti AM et al..  2017.  The association between detected drug resistance mutations and CD4+ T-cell decline in HIV-positive individuals maintained on a failing treatment regimen.. Antivir Ther.
Smit E, White E, Clark D, Churchill D, Zhang H, Collins S, Pillay D, Sabin CA, Nelson M, Winston A et al..  2017.  An association between K65R and HIV-1 subtype C viruses in patients treated with multiple NRTIs. J Antimicrob Chemother.
Collins IJ, Foster C, Tostevin A, Tookey P, Riordan A., Dunn DT, Gibb DM, Judd A.  2017.  Clinical Status of Adolescents with Perinatal HIV at Transfer to Adult Care in the UK/Ireland. Clin Infect Dis. Epub ahead of print
Le Vu S, Ratmann O, Delpech V, Brown A, Gill NO, Tostevin A, Fraser C, Volz E.  2017.  Comparison of cluster-based and source-attribution methods for estimating transmission risk using large HIV sequence databases.. Epidemics.
Ragonnet-Cronin M, Shilaih M, Günthard HF, Hodcroft E, Boni J, Fearnhill E, Dunn DT, Yerly S, Klimait T, Aubert V et al..  2016.  A Direct Comparison of Two Densely Sampled HIV Epidemics: The UK and Switzerland. Sci Rep. 6
TenoRes Study Group.  2016.  Global epidemiology of drug resistance after failure of WHO recommended first-line regimens for adult HIV-1 infection: a multicentre retrospective cohort study. Lancet Infect Dis.
El-Bouzidi K, White E, Mbisa JL, Sabin CA, Phillips AN, Mackie N, Pozniak A, Tostevin A, Pillay D, Dunn DT et al..  2016.  HIV-1 drug resistance mutations emerging on darunavir therapy in PI-naive and -experienced patients in the UK. J Antimicrob Chemother. 71(12)
De Luca A., Flandre P., Dunn DT, Zazzi M, Wensing A., Santoro MM, Günthard HF, Wittkop L., Kordossis T., Garcia F. et al..  2016.  Improved darunavir genotypic mutation score predicting treatment response for patients infected with HIV-1 subtype B and non-subtype B receiving a salvage regimen. J Antimicrob Chemother. 71:1352-60.
Antiretroviral Therapy Cohort Collaboration(ART-CC), Canadian Observational Cohort Collaboration(CANOC), UK Collaborative HIV Cohort Study(UK CHIC), Collaboration of Observational HIV Epidemiological Research in Europe(COHERE).  2016.  Mortality of treated HIV-1 positive individuals according to viral subtype in Europe and Canada: collaborative cohort analysis. AIDS. 30(3)
White E, Smit E, Churchill D, Collins S, Booth C, Tostevin A, Sabin CA, Pillay D, Dunn DT, UK HIV Drug Resistance Database et al..  2016.  No evidence that HIV-1 subtype C infection compromises the efficacy of Tenofovir-containing: Cohort study in the United Kingdom. J Infect Dis.